Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 508 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MS Clear all
Completed Phase 4 Interventional

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

NCT00206648
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaferon/Betaseron
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Jun 26, 2026, 5:14 PM EDT
Recruiting No phase listed Observational

Body Composition Outcomes in MS Patients

NCT07530718
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Safety of RG2077 in Patients With Multiple Sclerosis

NCT00076934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
RG2077 (CTLA4-IgG4m)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jun 26, 2026, 5:14 PM EDT
Not listed Phase 2 Interventional

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

NCT01466114
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
Interventions
estriol, Placebo, Norethindrone, Progestin Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Jun 26, 2026, 5:14 PM EDT
Completed No phase listed Observational Results available

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

NCT01535664
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Withdrawal of dalfampridine-ER 10mg
Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

NCT00436826
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Interferon-beta (IFN-beta)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
21
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS

NCT02606604
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RT 300: Lower Extremity Cycling
Device
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Jun 26, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Treating Anorectal Dysfunction in MS

NCT02609607
View directory record Official record
Conditions
Constipation, Fecal Incontinence, Multiple Sclerosis
Interventions
Bisacodyl, Placebo
Drug · Other
Lead sponsor
David Levinthal
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jun 26, 2026, 5:14 PM EDT
Completed No phase listed Observational

A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years

NCT01847287
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Jun 26, 2026, 5:14 PM EDT
Active, not recruiting No phase listed Observational

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05925049
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 26, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS

NCT04855825
View directory record Official record
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic, Motility Disorder, Cognitive Impairment
Interventions
Robotic Exoskeleton Rehabilitation, Conventional Gait Therapy
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

NCT01034579
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Blood sampling
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)

NCT04574024
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NBT-NM108
Drug
Lead sponsor
Suhayl Dhib-Jalbut, MD
Other
Eligibility
21 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients

NCT00001669
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
rhIGF-1 (CEP-151)
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 5:14 PM EDT
Recruiting Phase 4 Interventional

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

NCT07225361
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 26, 2026, 5:14 PM EDT
Active, not recruiting No phase listed Observational

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

NCT04495556
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jun 26, 2026, 5:14 PM EDT
Withdrawn Not applicable Interventional

Endeavor™ in Pediatric MS

NCT04445116
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Action Video Game Treatment
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 22 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

Iloperidone in Mixed States of Bipolar Disorder

NCT02413918
View directory record Official record
Conditions
Bipolar Disorder
Interventions
iloperidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

NCT00239993
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
glatiramer acetate, Warm compress prior to injection of glatiramer acetate
Drug · Procedure
Lead sponsor
Teva Neuroscience, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Fullerton, California • Miami, Florida • Springfield, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

NCT00401115
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
MS-R001 (rapamycin)
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Phoenix, Arizona • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2010 · Synced Jun 26, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

NCT06390930
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 26, 2026, 5:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

NCT04530955
View directory record Official record
Conditions
Injuries, Spinal Cord, CVA (Cerebrovascular Accident), Traumatic Brain Injury, MS (Multiple Sclerosis), Muscle Spasticity, Cerebral Palsy, Spastic
Interventions
Prometra II Programmable Pump - Flowonix Medical
Device
Lead sponsor
Culicchia Neurological Clinic
Other
Eligibility
22 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marrero, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Jun 26, 2026, 5:14 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

NCT01047319
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Laquinimod
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
Not listed
Enrollment
1,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
22
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jun 26, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

NCT01156311
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Jun 26, 2026, 5:14 PM EDT